(191): In CKD rats, ferroptosis inducer cisplatin (CP) reduced GSH and GPX4, while inhibitor desferrioxamine (DFO) elevated these markers, confirming ferroptosis modulation as an RF intervention. Here, GPX4 is linked to chronic kidney disease.